Costa F, van Klaveren D, Colombo A, et al. - Given the originally-proposed PRECISE-DAPT score represents a 5-item risk score supporting decision-making for dual antiplatelet therapy duration post-PCI, researchers investigated whether DAPT duration can be guided by a simplified version of the score based on 4 factors (age, hemoglobin, creatinine clearance, prior bleeding), and lacking white-blood cell count. Using the 4-item PRECISE-DAPT, experts grouped a total of 10,081 patients randomized to short (3–6 months) or long (12–24 months) DAPT regimen as per high (HBR defined by PRECISE-DAPT ≥ 25 points) or non-high bleeding risk (PRECISE-DAPT < 25) status. Long treatment duration was found to be related to higher bleeding rates in HBR but not in non-HBR patients, and was identified to be related to lower ischaemic risks in non-HBR, but not in HBR patients. Longer DAPT was associated with lower net clinical adverse events only in non-HBR patients. Findings showed retained potential of a 4-item simplified version of the PRECISE-DAPT score to classify patients who benefit from prolonged DAPT without concomitant bleeding liability from those who do not.